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Here, we report that the natural compound pentachloropseu-
dilin (PClP) acts as a reversible andallosteric inhibitor ofmyosin
ATPase andmotor activity. IC50 values are in the range from1 to
5M formammalian class-1myosins and greater than 90M for
class-2 and class-5myosins, andno inhibitionwas observedwith
class-6 and class-7 myosins. We show that in mammalian cells,
PClP selectively inhibits myosin-1c function. To elucidate the
structural basis for PClP-induced allosteric coupling and iso-
form-specific differences in the inhibitory potency of the com-
pound, we used amultifaceted approach combining direct func-
tional, crystallographic, and in silico modeling studies. Our
results indicate that allosteric inhibition by PClP is mediated by
the combined effects of global changes in protein dynamics and
direct communication between the catalytic and allosteric sites
via a cascade of small conformational changes along a conserved
communication pathway.
Myosins are a large superfamily of molecular motors that
move along actin filaments in an ATP-dependent manner. The
versatile and indispensable role of myosins as mediators of a
wide range of transport and chemo-mechanical signal trans-
duction events is generally accepted. Due to their rapid, condi-
tional, and reversible mode of action, small molecule modula-
tors of protein function are useful tools in cell biological
research and can serve as lead compounds in the development
of therapeutic agents (1, 2). The use of small molecule effectors
of myosin function such as N-benzyl-p-toluenesulfonamide
and blebbistatin helped to provide important new insights in a
range of cellular functions that require the active participation
of at least one member of the myosin family. Compounds such
as blebbistatin and N-benzyl-p-toluenesulfonamide display
preferred interactions with selectedmembers ofmyosin class-2
(3, 4). However, there exists a requirement to develop specific
inhibitors for other classes of myosins.
Recently, we described the total synthesis of halogenated
pseudilins, natural products containing a 2-arylpyrrole moiety,
and their synthetic analogues (5). Pentabromopseudilin (PBP)2
was identified as a potent inhibitor of vertebrate myosin-5
motor activity. An IC50 of 400 nM was determined for the PBP-
mediated inhibition of the ATPase activity of vertebrate myo-
sin-5 (6). Based on this finding, we screened related compounds
to identify myosin effectors with altered selectivity for the
members of different myosin classes (7). Pentachloropseudilin
(PClP), a close chemical and structural analog of PBP, was iden-
tified as a potent inhibitor of class-1 myosins.
Here, we describe the effects of PClP on actomyosin kinetics,
myosin motor function, and cellular morphology. Co-crystalli-
zation trials with class-1myosins in the presence of PClP failed.
Because most of the class-1 myosin motor domains have
50–60% sequence similarity with class-2 myosin motor
domains, we used Dictyostelium discoideum myosin-2 as a
model system to interpret the binding site of PClP in other
myosin isoforms. The resulting structure shows that the inhib-
itor binds in the same allosteric pocket as PBP, but the confor-
mation of the inhibitor and details of its interaction with myo-
sin are different. Molecular modeling and docking studies
based on the x-ray crystallographic results were used to explain
the preferred binding of PClP to class-1 myosins.
EXPERIMENTAL PROCEDURES
Protein Preparation—Wepurified His-taggedmotor domain
constructs of myosin-1E, myosin-1B, myosin-2, andmyosin-5b
from D. discoideum comprising amino acids 1–698, 1–698,
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1–761, and 1–829, respectively, by Ni2 chelate affinity chro-
matography (8, 9). FLAG-tagged truncated Rattus norvegicus
myosin-1b and myosin-1c consisting of the motor domain and
first IQ domain were prepared as described previously (10, 11).
Amino acids 1–816 of human myosin-6 and 1–747 of human
myosin-7awere fused to an artificial lever arm and in the case of
myosin-7a additionally to an enhanced yellow fluorescent pro-
tein (EYFP) fluorescence marker. His-tagged proteins were
overproduced in the baculovirus/Sf9 system and purified by
Ni2 chelate affinity chromatography and gel filtration.
Synthesis of PClP—We synthesized PClP using Ag(I)-cata-
lyzed cyclization to the pyrrole ring system (5).
Inhibition ofMyosin-1c-dependent Cellular Processes—HeLa
cells were grown to 50% confluence in RPMI 1640 containing
10% fetal calf serum, 2 mM L-glutamine, and 100 units/ml pen-
icillin and 100 g/ml streptomycin and treated for 16 h with 1
M PClP in DMSO. To reduce the expression of myosin-1c,
HeLa cells were transfected twice with control siRNA or siRNA
specific for myosin-1c on days 1 and 3 using Oligofectamine
(Invitrogen). PClP-treated and siRNA knockdown cells were
fixed with 4% paraformaldehyde, permeabilized with 0.1% Tri-
ton X-100, blocked with 1% BSA in PBS, and processed for
indirect immunofluorescence using a monoclonal antibody to
Lamp1 (Developmental StudiesHybridomaBank, University of
Iowa) to label lysosomes, Alexa Fluor 568-labeled phalloidin
(Molecular Probes) to visualize actin filaments, and DAPI to
stain the nucleus.
Kinetic Measurements—We measured basal and actin-acti-
vated Mg2-ATPase activities using the NADH-coupled assay
described previously (8, 12). The assay was performed at 25 °C
in a buffer containing 25 mMHEPES, pH 7.4, 25 mM KCl, and 4
mM MgCl2. The effect of PClP on the actin-activated myosin
ATPase activity was measured in the presence of 20 M F-actin
and 1 mM ATP. PClP was added to the reaction mixture in the
absence of nucleotide and incubated for 20min before the reac-
tion was started by the addition of ATP. Each reaction mixture
including the controls contained 2.5%DMSO that was used as a
solvent for the compound. Data were corrected for NADH
absorption at 340 nm and expressed as relative myosin ATPase
activity (in percentage of control), and additional data analysis
was carried out with Origin 8 (OriginLab Corp.). Transient
kinetic experiments were performed at 20 °C in an assay buffer
containing 20 mM MOPS, 100 mM KCl, 5 mM MgCl2, 1 mM
dithiothreitol, pH 7.0, with an SF-61DX singlemixing stopped-
flow system (TgK Scientific Ltd.). PClP was excited at a wave-
length of 365 nm, and fluorescencewas detected at 416 nm.The
in vitromotility assay was performed with a construct consist-
ing of D. discoideum myosin-1B motor domain fused to an
artificial lever arm. We measured sliding filament velocity at
25 °C using an Olympus IX81 inverted fluorescence micro-
scope. The coverslip surface was treated with chlorotrimethyl-
silane (Sigma), and Pluronic F-127 (Sigma) served as a blocking
agent. The program DiaTrack 3.01 (Semasopht) was used for
automated actin filament tracking. Statistical data analysis was
performed with Origin 8 (OriginLab Corp.).
Crystallography—D. discoideum myosin-2 motor domain
construct M761 (15 mg/ml) was preincubated for 1 h at 4 °C
with a mixture of sodiummeta-vanadate (2 mM), ADP (2 mM),
and PClP (0.5 mM) before crystallization. D. discoideum myo-
sin-2:PClP complex was crystallized in the presence of 50 mM
HEPES, pH 7.4, 140 mM NaCl, 11% w/v PEG 8000, 2% (v/v)
2-methyl-2,4-pentanediol, 5 mM MgCl2, 5 mM DTT, and 1 mM
EGTA using the vapor diffusion hanging-drop method. The
protein and the reservoir solution were mixed in a 1:1 ratio for
crystallization. Before data collection, we soaked crystals for 5
min at 4 °C in a cryo-protection solution containing reservoir
solution supplementedwith 25% ethylene glycol. Subsequently,
crystals were flash-cooled in liquid nitrogen. Crystals of space
groupC2221 produced diffraction data to 2.5Å resolution.Data
were collected with a wavelength of 0.9871 Å at BESSY (BL14-
1). Data processing and scaling were performed with XDS (13).
Molecular replacement andmodel refinement were performed
using CNS, excluding a random 5% of the data for cross-valida-
tion (14). Model building and validation were carried out with
COOT (15) and MolProbity (16). Statistics are summarized in
Table 1. Coordinates were deposited with Protein Data Bank
(PDB) ID: 2XEL.
In Silico Modeling—Homology models of class-1 myosins
(D. discoideummyosin-1B (SwissProt: P34092),Rattus norvegi-
cus myosin-1b (SwissProt: Q05096), R. norvegicus myosin-1c
(SwissProt: Q63355), class-2 (Oryctolagus cuniculus myosin-2
(GenBankTM: AAA74199)), and class-5 myosins (D. discoi-
deummyosin-5b (SwissProt: P54697)) were built using MOD-
ELLER 9v6 (17). The motor domain structure ofD. discoideum
myosin-1E (1LKX) (18) was used as template to buildD. discoi-
deum myosin-1B, R. norvegicus myosin-1b, and R. norvegicus
myosin-1c myosin motor domains. The motor domain struc-
tures of D. discoideum myosin-2 (2JJ9) (6) and G. gallus myo-
sin-5a (1OE9) (19) were used as templates to buildO. cuniculus
myosin-2 and D. discoideum myosin-5b motor domains,
respectively. All motor domain models of myosins were built
using closely related pre-power stroke statemotor domain tem-
plate structures with sequence similarity greater than 60%.
Missing loop regions in the homology models were built by
Modeler followed by energy minimization using GROMACS 4
(20).
Docking—The ligand (PClP) was generated and energy-min-
imized with ChemDraw (CambridgeSoft). Protein input files
for docking were prepared by GOLD (21). Initially, we per-
formed blind docking of PClP for all themyosins examined.We
found PClP preference to the PBP binding pocket (with highest
Goldscore of 30–40 depending on myosin isoform). Further,
we focused on the PClP binding site based on blind docking
results and also from the experimental binding mode of PClP.
We performed local docking using the partial flexible docking
feature of GOLD, 8–10 residues in each case, for protein side
chains in the binding pocket and limited the search to a radius
of 10 Å from the active site.
The binding pocket was defined to comprise all residues
within 10 Å of atom 2746 (-N atom of Lys-186 in D. discoi-
deum myosin-1B), atom 1523 (-N atom of Lys-189 in R. nor-
vegicusmyosin-1c), atom 1515 (-N atom of Lys-192 in R. nor-
vegicus myosin-1b), atom 2789 (-N atom of Lys-186 in
D. discoideum myosin-1E), and atom 4234 (-N atom of Lys-
289 in D. discoideum myosin-5B). Docking was performed
using the “Genetic algorithm” implemented inGOLD.Weused
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the “Goldscore-Chemscore” protocol. In this protocol, docking
poses produced with the Goldscore function are used for initial
scoring, and then theChemscore function is used for final rank-
ing. Twenty solutions were generated for each myosin. In all
instances, at least one of the top five solutions (Goldscore
35–40) converged to a similar pose for the myosins tested. The
best poses deviated by1 Å, when compared with the experi-
mental ligand bound structure (2XEL).
RESULTS ANDDISCUSSION
PClP Is a Potent Inhibitor of Class-1 Myosins—To elucidate
the inhibitory potency and selectivity of PClP for individual
myosin isoforms, we tested the effect of the compound on the
ATPase activity ofmyosins fromdifferent classes in the absence
and presence of filamentous actin (F-actin). The addition of
PClP greatly decreased the rate of actin-activatedATP turnover
formembers ofmyosin classes 1, 2, and 5, whereas humanmyo-
sin-6 and myosin-7a motor domain constructs showed no sign
of inhibition in the presence of 100 M PClP. The most potent
inhibition was observed for class-1 myosins. Plots of the
observed rates against the logarithm of inhibitor concentration
could be fitted to sigmoidal curves (Fig. 1A). The IC50 values for
D. discoideummyosin-1B,R. norvegicusmyosin-1b, andR. nor-
vegicus myosin-1c correspond to 1.0, 5.0, and 5.6 M, respec-
tively. The potency of PClP for the inhibition of class-2 and
class-5 myosins is considerably lower. IC50 values correspond-
ing to 126, 91, and 99 M were observed with D. discoideum
myosin-2, O. cuniculus myosin-2, and D. discoideum myosin-
5b, respectively (Fig. 1A).
To investigate the interaction of PClPwith class-1myosins in
detail, we took advantage of the 30% increase in fluorescence
intensity of the compound that occurs upon binding tomyosin.
Stopped-flow transients observed following the rapidmixing of
PClP with myosin motor domain constructs are well described
by single exponential functions in the absence and presence of
F-actin or nucleotides. The observed rate constants are linearly
dependent on the PClP concentration in the range from 1 to 10
M (Fig. 1B). A typical transient obtained for PClP binding to
D. discoideummyosin-1B is shown in Fig. 1C in the inset. In the
absence of both F-actin and nucleotides, an apparent second-
order rate constant for PClP binding to D. discoideum myo-
sin-1B (kI  0.48  0.04  103 M1s1) is given by the
gradient of the plot, whereas the y-intercept defines an appar-
ent dissociation rate constant of kI  2.4  0.2  103 s1.
The ratio kI/kI defines an apparent dissociation equilibrium
constant (KI) of 5.0 0.9M. Alternatively, theKI forD. discoi-
deum myosin-1B can be determined by plotting the observed
changes in fluorescence amplitude against the PClP concentra-
tion (Fig. 1C). The resulting data are well described by a hyper-
bola and give a value of 4.2 0.8 M for KI. In the presence of
saturating concentrations of F-actin, values of 0.22  0.04 
103M1s1, 0.52 0.1 103 s1, and 2.4 0.8M for kI,
kI, and KI are observed (data not shown). Additionally, we
determined the binding kinetics of PClP to D. discoideum
myosin-1B during active ATP turnover in the presence of 1
mM ATP (Fig. 1B, inset). When compared with the apo state,
the apparent second-order rate constant for PClP binding is
15-fold increased (kI,ATP  7.19  0.25  103
M1s1), whereas the apparent dissociation rate constant is
only 5-fold increased (kI,ATP 11.8 1.8 103 s1). This
gives an apparent dissociation equilibrium constant (KI,ATP)
of 1.64  0.32 M, which is in good agreement with the IC50
value of 1 M observed for D. discoideum myosin-1B in the
ATPase assay.
PClP Is a Reversible Inhibitor of Myosin Motor Activity—PClP
binding reduces the affinity of myosin for F-actin in the pres-
ence of ATP and the coupling between actin and nucleotide
binding sites. To estimate the extent to which PClP binding
affects coupling, we determined the ATPase activity for D. dis-
coideummyosin-1B over the range from1 to 70MF-actin (Fig.
1D). Values for kcat and Km(actin) were estimated from fits of
hyperbolic functions to the data. The kcat value of 0.45  0.03
s1 in the absence of PClP is reduced to 0.3  0.02 s1 in the
presence of 1 M PClP. The addition of 5 M PClP results in a
further decrease in kcat to 0.07  0.04 s1. The corresponding
Km(actin) values from theMichaelis-Menten fits are 17.0 3.0
M (in the absence of PClP), 15.6 3.1 M (at 1 M PClP), and
84.0  77 M (at 5 M PClP). The apparent second-order rate
constant for F-actin binding in the presence of ATP (kcat/
Km(actin)) is a direct measure of the coupling efficiency
between the nucleotide and actin binding sites. The addition of
5 M PClP leads to a more than 30-fold reduction in coupling
efficiency from 0.028 to 0.00088 M1s1. A direct weakening
effect on the actomyosin interaction is indicated by observa-
tions following the addition of PClP to actomyosin-decorated
glass surfaces. AD. discoideummyosin-1B motor domain con-
struct, fused to an artificial lever arm of 12 nm in length, moves
F-actin with an average velocity of 1.01 0.13 m s1 in the in
vitro motility (8). The addition of 2 M PClP results in a more
than 2-fold reduction of the average sliding velocity to 0.51 
0.08 m s1 (Fig. 1E). Higher concentrations of PClP lead to
dissociation of the filaments from the assay surface.Washout of
the inhibitor results in complete recovery of motile activity.
This result shows that inhibition of myosin motor activity by
PClP is reversible (Fig. 1F).
PClP Inhibits Cellular Functions of Human Myosin-1c—We
next tested whether PClP inhibits myosin-1c in vivo. In mam-
mals, myosin-1c is involved in a number of highly specialized
tissue-specific functions, such as the adaptation of mechano-
electrical transduction in the hair cells of the inner ear and the
translocation of glucose transporter type 4 (GLUT4) transport-
ers to the plasma membrane in adipocytes. In addition, myo-
sin-1c appears to function in the late endocytic pathway, which
delivers endocytosed macromolecules to the lysosome for deg-
radation (22). This observation is supported by our demonstra-
tion that inhibiting myosin-1c function by RNA interference
causes defects in lysosome morphology and intracellular local-
ization of this organelle. As shown in Fig. 2A, loss of myosin-1c
expression after transfection of siRNA specific for myosin-1c
causes a collapse and clustering of Lamp1-positive lysosomes in
the perinuclear region on one side of the nucleus. Furthermore,
the lysosomes in thesemyosin-1c knockdowncells dramatically
change their morphology and become large, swollen ring-like
structures (Fig. 2A, inserts panel). To test the activity of PClP in
a cellular environment, HeLa cells were treated for 16 h with
non-toxic concentrations of PClP between 1 and 5 M. Cyto-
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toxic effects of PClP in this cell type were only observed at
concentrations above 25 M. Interestingly, in PClP-treated
HeLa cells, we observed identical changes in lysosome mor-
phology and distribution (Fig. 2A) as observed in myosin-1c
siRNAknockdown cells. These observationswere quantified by
measuring the number and size of lysosomes in a large popula-
tion of cells (7000 cells) using high throughput microscopy
and fully automated imaging software. Although there was no
significant change in the number of lysosomes uponmyosin-1c
siRNA transfection or PClP treatment (data not shown), the
total area covered by these organelles was significantly in-
creased under these conditions due to the enlarged size of the
FIGURE 1. PClP-induced changes inmyosin function. A, effect of PClP onmyosin actin-activated ATPase activity. The semi-logarithmic plot shows the [PClP]
dependence of the inhibition for D. discoideum myosin-1B (Vmax 0.54 0.10 s
1) (), R. norvegicus myosin-1b (Vmax 0.39 0.08 s
1) (‚), R. norvegicus
myosin-1c (Vmax  0.75  0.23 s
1) (E), and D. discoideum myosin-2 (Vmax  0.53  0.03 s
1) (). The concentrations of PClP required for half-maximal
inhibition (IC50) of the differentmyosinmotorswere determined from sigmoidal fits of the data. Rel., relative. Error bars indicate S.E. B, binding anddissociation
kinetics for the interactionofPClPwithD. discoideummyosin-1B. Theobserved rate constants for theexponential increase in fluorescence intensity that follows
rapid mixing of PClP with D. discoideum myosin-1B display a linear dependence on [PClP] in the range from 1 to 10 M. The gradient of the plot specifies an
apparent second-order rate constant for PClP binding to D. discoideum myosin-1B (kI 0.48 0.04 10
3 M1s1), whereas the y-intercept defines an
apparent dissociation rate constant of kI 2.4 0.2 10
3 s1. In the presence of 1mM ATP, a 15-fold increase in the apparent second-order rate constant
for PClP binding (kI,ATP 7.19 0.25 10
3M1s1) and a 5-fold increase in the apparent dissociation rate constant (kI,ATP 11.8 1.8 10
3 s1) are
observed (inset). Error bars indicate S.E. C, direct determination of the affinity of PClP for D. discoideum myosin-1B in the absence of F-actin and nucleotides.
Shown is the [PClP] dependence of the change in fluorescence intensity. A hyperbolic fit to the data gives a KI of 4.2 0.8M for PClP binding toD. discoideum
myosin-1B. The inset shows the increase in fluorescence intensity that follows rapidmixing of PClP withD. discoideummyosin-1B. The process can be fitted to
a single exponential function. Error bars indicate S.E.D, PClP-mediated inhibition of the actin-activatedATPase activity ofD. discoideummyosin-1B. TheATPase
activity at increasing concentrations of F-actin from 0 to 70M is shown. Hyperbolic Michaelis-Menten functions are fitted to the data at 0 (f), 1 (F), and 5M
PClP (Œ). Error bars indicate S.E. E, D. discoideummyosin-1B moves actin filaments in the in vitromotility assay with an average velocity of 1.01 0.13 m s1
(dark gray bars). In the presence of 2 M PClP (light gray bars), filament velocity is reduced to 0.51  0.1 m s1. F, a complete washout of the inhibitor
reconstitutes the motile activity of uninhibited D. discoideummyosin-1B with an average velocity of 1.01 0.3 m s1.
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lysosomes (Fig. 2B). Taken together, these results indicate that
inmammalian cells, PClP inhibits myosin-1c function at a con-
centration of 1 M.
Structural Basis of PClP-mediated Inhibition—Co-crystalli-
zation studies were performed with motor domain constructs
derived from three class-1 isoforms. However, these constructs
proved refractory to crystallization. Therefore, we co-crystal-
lized and solved the structure of the D. discoideum myosin-2
motor domain complexed toMg2-ADP-meta-vanadate in the
presence of PClP. Crystals of space group C2221 produced dif-
fraction data to 2.5 Å resolution (Table 1). The crystallographic
results are in good agreement with the allosteric mechanisms
inferred from the kinetic data. PClP binds near actin binding
residues at the tip of the 50-kDa domain, at a distance of16 Å
from the nucleotide binding site (Fig. 3A). This is the same
allosteric binding pocket previously described for PBP (6).
However, both the conformation of PClP and the details of the
interaction with myosin residues in the binding pocket differ
from those observedwith PBP (supplemental Fig. S2). The aver-
age root mean square deviation for PClP and PBP is 2.3 Å. The
planar anti-conformer of PClP binds to myosin. This differs
from the binding mode of PBP, where the syn-conformer is
observed to bind with the phenyl and pyrrole ring systems bent
12° out of plane and twisted 20° against each other (6) (supple-
mental Fig. S2). Three helices and three loops contribute to
PClP binding. Toward the actin binding interface, PClP is
enclosed by the strut loop (Asn-588-Gln-593) and loop 2 (Asp-
614-Thr-629). Toward the core of themotor domain, the bind-
ing pocket is lined by helix 10 (Lys-265-Val-268) and helix 18
(Val-411-Leu-441) from the upper 50-kDa domain. Addition-
ally, helix 26 (Val-630-Glu-646) and the loop connecting 7
(Ile-253-Leu-261) with helix 10 contribute to the binding
pocket (Fig. 3, B and C). The total protein surface area in con-
tact with PClP comprises 240 Å2.
FIGURE 2. Inhibition of Homo sapiens myosin-1c by PClP causes clus-
tering and swelling of mammalian lysosomes. A, in control HeLa cells
without PClP treatment (panels a and b) or siRNA transfection (panels e
and f), lysosomes are small vesicular organelles that are distributed
throughout the cells. In PClP-treated (panels c and d) and myosin-1c
siRNA-transfected cells (panels g and h), the lysosomes are clustered in the
perinuclear region, where they are frequently tethered to form larger
aggregates. In addition, they are significantly larger in size and appear
swollen. The left panels (panels a, c, e, and g) show confocal images of a
group of cells stained for lysosomes with an antibody to Lamp1. The mid-
dle panels (panels b, d, f, and h) show enlarged confocal images of single
cells, further highlighting the aggregated, swollen lysosomes in PClP-
treated and myosin-1c siRNA-depleted cells. On the right, in the inserts
panels, the panels (b, d, f, and h) are higher magnifications of the boxed
regions. Bars, 10 m. B, to quantify swelling of lysosomes, HeLa cells
treated with/without PClP and mock- or myosin-1c siRNA-transfected
cells were labeled with antibodies to Lamp1 for high throughput micros-
copy. Automated imaging software was used to quantify the total area
covered by lysosomes per single cells. A significant increase in the lyso-
somal area was observed in PClP- andmyosin-1c siRNA-treated cells when
compared with control cells. A total number of 7775 cells from three inde-
pendent experiments, each performed in triplicate, was analyzed. Error
bars indicate S.E. *, p 	 0.05, **, p 	 0.005. C, to verify myosin-1c knock-
down, cell lysates of mock- and myosin-1c siRNA-treated HeLa cells were
blotted and probed with antibodies to myosin-1c and -tubulin as a load-
ing control.
TABLE 1
Summary of data collection and refinement statistics
Myosin-2-ADPVO3-
pentachloropseudilin
Data collection
Space group C2221
Wavelength (Å) 0.9871
Cell dimensions
a, b, c (Å) 89.53, 147.49, 153.78
, ,  (°) 90, 90, 90
Rsym (%) 6.2 (48.3)a
I/I 15.97 (5.01)
Completeness (%) 99.8 (100)
Redundancy 8.2 (8.4)
Refinement
Resolution (Å) 24.6-2.5
Rwork/Rfree (%) 22.9/25.3
No. of reflections working/test set 33755/1777
No. of atoms
Protein 6240
Ligands/ions 48/1
Water 458
r.m.s.b deviations
Bond lengths (Å) 0.008
Bond angles (°) 1.6
Ramachandran plot (% Favored/allowed/
outliers)b
92.3/7.7/0
a Values in parentheses are for highest-resolution shell (2.60–2.50).
b r.m.s., root mean square.
c Residues in favored, allowed, and outlier regions of the Ramachandran plot as
reported by MolProbity (21).
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Anetwork of interactions stabilizes PClP binding. Important
binding site rearrangements include a change in the orientation
of the side chain of Lys-265, which moves 3.1 Å from its posi-
FIGURE 3. StructureofD. discoideummyosin-2motordomain in complexwithPClPandMg2-ADP-meta-vanadate.A, sectionof the2Fo Fcelectrondensity
omit map, contoured at 1.0 , depicting the PClP binding site. B, overall view of themyosinmotor domain in ribbon representation. PClP and ADPVO3 are shown in
spheresmode;N-terminal residuesareshowningreen, andtheC-terminalconverter regionareshownincyan.C, close-upviewofallostericbindingpocketwithprotein
residues in graphic representation and PClP in stick representation. Important structural features around the binding pocket are colored and labeled accordingly.
D, schematic view of the anti-conformer of PClP and its contact residues. Contacts with residues closer than 4 Å are shown.
FIGURE4.SurfacerepresentationofthePClPbindingsite indifferentmyosin
isoforms. Highly conserved residues interacting with PClP are shown in pink.
Non-conserved residues interactingwith PClP are coloredgreen. Amino acid res-
iduesare indicatedusingthesingle lettercode.A–F, PClPbindingpocketofD. dis-
coideum (Dd)myosin-2 crystal structure (*, reference structure) (A);D. discoideum
myosin-1B (B); R. norvegicus (Rn) myosin-1b (C); R. norvegicus myosin-1c (D);
D. discoideummyosin-1E (E); andD. discoideummyosin-5b (F).
TABLE 2
PCIP binding site with contact residues for different myosin isoforms
Selected residues interacting with PCIP are shown for D. discoideum (Dd) myosin-
1B, R. norvegicus (Rn) myosin-1b, R. norvegicusmyosin-1C,O. cuniculus (Oc) myo-
sin-2 and D. discoideum myosin-5b. The half maximal inhibitory concentration of
PCIP (IC50) is shown for each myosin isoform. Residues in the binding pocket are
color-coded according to their polarity. Uncharged polar residues are shown in
yellow, acidic residues are in green, basic residues are in red, and non-polar residues
are in gray.
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tion in the uninhibited form to facilitate formation of a hydro-
gen bond between the -amino group and the hydroxyl group of
PClP. The amino group of the pyrrole ring interacts with the
main chain carbonyl groups of Ile-617 and Ser-619. Two water
molecules form part of a network of interactions that involves
the main chain carbonyl groups of Ala-420 and Pro-591, the
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side chains of Lys-265 and Asp-590, and the hydroxyl and
2-chloro groups of the phenyl ring. Additional interactions are
formed between the side chains of Arg-428 and Leu-431 and
chloro groups of the inhibitor (Fig. 3D).
Myosin Isoform-dependent Interactions with PClP—To
rationalize the structural basis for the experimentally
observed preferred inhibition of class-1 myosins, we per-
formed docking studies using the crystal structure of the
motor domain of D. discoideum myosin-1E (1LKX) and
homology models of D. discoideum myosin-1B, D. discoi-
deummyosin-5b, R. norvegicusmyosin-1b, and R. norvegicus
myosin-1c in the pre-power stroke state. For all myosin iso-
forms tested, initial blind docking studies predict that PClP
binds to the same site described above for the complex with
the D. discoideum myosin-2 motor domain. To achieve bet-
ter sampling of the translational, rotational, and torsional
degrees of freedom of the ligand, we performed local docking
using a 10 Å grid around this site. The highest ranked bind-
ing poses are shown in Fig. 4, and the predicted contact
residues for PClP in complex with the individual myosin
isoforms are shown in Table 2. The results of the docking
studies indicate that the contact between the hydroxyl group
of PClP and Lys-265 is a common and important feature of
the interaction betweenmyosin and effector molecule. Addi-
tionally, the polarity of the allosteric binding pocket appears
to make an important contribution to the preferred binding
of PClP to class-1 myosins (Fig. 4 and Table 2).
Energetic Coupling between Active and Allosteric Binding
Sites—Because x-ray crystallography favors particular stable
intermediates, observable changes resulting from the bind-
ing of an allosteric effector tend to be subtle in terms of
impact on an experimentally determined three-dimensional
structure (23). Experimental manifestations of an allosteric
effect are thus frequently limited to the rates of interchange
between different conformer populations at any given point
along the enzymatic reaction coordinate (24). Typical for
this type of energetic coupling between the active and allo-
steric sites, the available x-ray structures in the presence
(2XEL) and absence (2JJ9) of bound PClP do not indicate a
major conformational change. The myosin backbone C
atoms in both structures superimpose with a root mean
square deviation of 0.4 Å.
Analysis of pre-power stroke state myosin structures in
the absence and presence of PClP indicates the existence of a
communication pathway that transmits information
between the allosteric and nucleotide binding sites. A net-
work of hydrogen bonds extends over a distance of 19 Å,
forming a direct link between PClP and the -phosphate
position of ATP. The network involves side chain as well as
main chain interactions. Lys-265 is the starting point for this
allosteric relay mechanism. The -amino group of Lys-265
moves 3.1 Å from its position in the uninhibited form to
facilitate an interaction with the hydroxyl group of PClP.
The salt bridge connecting Arg-238 in Switch I with Glu-459
in Switch II forms part of the relay path. The distance
between Arg-238 and Glu-459 increases by 0.3 Å upon PClP
binding. Other key residues involved in the relay mechanism
are Ser-236 and Ser-237 in Switch I, Gln-468 in the relay
helix, and residues Lys-265, Ser-266, and Arg-267 in helix 10
(Fig. 5, A and B). The major consequence of the rearrange-
ments induced by PClP binding is the displacement of the
“catalytic water” molecule at the active site, as indicated by
comparison of 2Fo  Fc electron density maps (Fig. 5, C and
D). Electron density for a water molecule positioned appro-
priately for in-line attack to the -phosphate analog of nucle-
otide is present in the active site of the pre-power stroke
state structures with bound ADPVO3 (2JJ9), ATPS,
(1MMG), ADP-AlF4 (1W9L), and N-methylanthraniloyl-
ADP-BeFx (1D1C) (6, 25, 26) but absent in structure 2XEL
with bound ADPVO3 and PClP (supplemental Fig. S3). The
detailed analysis of the PClP bound structure enabled us to
identify the same allosteric pathways in the myosin motor
domain structures with bound PBP (2JHR) and tribromodi-
chloropseudilin (2XO8) (6, 7). The inhibitor-induced change
in Lys-265 rotamer, the movement of the same key residues
along the relay path, and the absence of the catalytic water
are shared features by these structures.
Conclusion—Allosteric effectors that target myosin
motors with high affinity and specificity are key tools in cyto-
skeletal research. Here, we report that the natural product
PClP can be used as a potent and selective inhibitor of class-1
myosins in cell biological studies. The optical properties of
the compound allow the direct observation of its binding
interactions with myosins. Our detailed kinetic and struc-
tural analysis indicate that PClP is a non-competitive,
reversible inhibitor of myosin motor activity that acts in part
by reducing the coupling between the actin and nucleotide
binding sites. Isoform-specific differences in the potency of
PClP-mediated inhibition can be rationalized by differences
in the size and polarity of the allosteric binding pockets of
myosin isoforms (Fig. 4). In contrast to these differences in
size and polarity, the residues involved in the relay pathway
connecting the allosteric and active sites over a distance of
19 Å show a higher degree of conservation between myosin
isoforms (supplemental Fig. S1). This suggests that the same
communication pathway plays an important role in coupling
information between the actin and nucleotide binding sites
during normal catalytic turnover.
FIGURE 5.Schematic illustrationof the relaypathway connecting theallosteric pocket and thenucleotidebinding site in the absence andpresenceof
PClP. A, residues involved in the relay pathway and selected side chains are shown for themyosinmotor domain in the absence of PClP (2JJ9). B, PClP-induced
changes in the orientation of selected side chains along the relay pathway. Distances between residues are shown as dashed lines indicated in Å. Main chain
interactions are not explicitly shown. C, in the absence of PClP, the 2Fo  Fc electron density for MgADPVO3 in structure 2JJ9 allows the unambiguous
placementof anextrawatermolecule. Thiswatermolecule is ideally positioned for inline attack relative toVandcan thus act as catalyticwater.D, PClPbinding
induces the displacement of the catalytic water. MgADPVO3 fits into the 2Fo Fc electron densitymap from structure 2XEL obtained in the presence of PClP.
The2Fo Fcelectrondensitymapsare contouredat 1.5. Side chains andADP-meta-vanadate are shown in stickmode.Magnesium ion (green) andwaters (red)
are shown as spheres;Wlyt denotes the lytic water molecule, andWhelp denotes the helper water.
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